Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018

Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD

Labeling adds two of the company’s most widely used high voltage devices into MRI-compatible portfolio

Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD

January 3, 2018 — Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for the Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) and Fortify Assura implantable cardioverter defibrillator (ICD). The approvals follow recent MR-conditional labeling approvals for the Assurity MRI pacemaker, Ellipse ICD and associated MRI-compatible leads, and further expand Abbott's portfolio of MRI-ready devices for patients indicated for ICDs and/or CRT-D devices who may need an MRI in the future.

Physicians utilize ICDs to restore normal heart rhythms in patients at risk for experiencing potentially life-threatening heart rhythms; they implant CRT-D devices to help the lower chambers of the heart beat in rhythm in patients battling progressive congestive heart failure and improve blood flow throughout the body. For some patients, the potential need for a future MRI has made MR-conditional labeling important as physicians assess therapies and device options. As a result, Abbott has done extensive testing to demonstrate that these devices are safe in the most commonly-used MRI scanners.

In addition to MRI compatibility, Abbott's Fortify Assura ICD and Quadra Assura MP CRT-D also include the company's suite of TailoredTherapy features, which are designed to provide physicians additional flexibility and control in how they deliver therapy to treat their patient's cardiac arrhythmias and congestive heart failure, even as their patient's therapy needs change over time. With the TailoredTherapy feature set, the Fortify Assura ICD and Quadra Assura MP CRT-D help protect against the delivery of unnecessary therapy and continuously evaluate the condition of a lead to consistently deliver appropriate therapy. Combined with MRI compatibility, these features offer physicians additional options to leverage when managing patient care.

The Quadra Assura MP CRT-D also offers Abbott's proprietary MultiPoint Pacing and SyncAV technology to provide additional options for CRT patients who are not responsive to traditional cardiac resynchronization therapy. With MultiPoint Pacing, Abbott allows physicians to "individualize" cardiac resynchronization therapy and shift their patient's treatment options from a single point of pacing to multiple options to better deliver therapy where needed. Abbott's SynvAV software allows a CRT device to detect real-time changes in a patient's cardiac condition and adjust therapy accordingly.

As with all Abbott cardiac rhythm management devices, all therapy data captured by the Fortify Assura and Quadra Assura MP devices can be directly, securely and wirelessly sent to a patient's doctor through the Merlin.netTM Patient Care Network. This communication allows physicians to remotely monitor their patient's therapy and assess any need for intervention.

For more information: www.sjm.com

Related Content

Abbott Receives FDA Approval for MR-Conditional Labeling of Assurity Pacemaker

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD

St. Jude Medical Announces U.S. Launch, Implants of MultiPoint Pacing

St. Jude Medical Expands Heart Failure Portfolio with SyncAV CRT Technology


Related Content

News | Cardiac Imaging

September 2, 2022 — A randomized trial in more than 45,000 men has suggested that cardiovascular screening including ...

Home September 02, 2022
Home
News | Cardiac Imaging

September 2, 2022 — In an innovative, pragmatic randomized trial, high-dose influenza vaccination in older adults was ...

Home September 02, 2022
Home
News | Cardiac Imaging

August 25, 2022 — Imperfect current propagation in the heart is at the root of most cardiac diseases. Thanks to a novel ...

Home August 25, 2022
Home
News | Cardiac Imaging

July 14, 2022 – AvoMD, a next-generation application-based clinical decision support platform, is working with the ...

Home July 14, 2022
Home
Feature | Cardiac Imaging | By Ronny Shalev, Ph.D.

Artificial intelligence’s (AI) applicability in cardiac imaging is rapidly growing and was a major topic of discussion ...

Home June 28, 2022
Home
News | Cardiac Imaging

June 24, 2022 — The Radiological Society of North America (RSNA) reports that Coronary Artery Calcium (CAC) scoring with ...

Home June 24, 2022
Home
News | Cardiac Imaging

June 23, 2022 — New research from the Smidt Heart Institute at Cedars-Sinai shows for the first time that the path ...

Home June 23, 2022
Home
News | Cardiac Imaging

May 2, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), routine visual ordinal coronary artery calcium ...

Home May 02, 2022
Home
News | Cardiac Imaging

April 11, 2022 — Radiation to the heart during treatment for locally advanced lung cancer is associated with an ...

Home April 11, 2022
Home
News | Cardiac Imaging
February 21, 2022 – Acute coronary syndromes (such as heart attacks) and strokes are a leading cause of morbidity and ...
Home February 21, 2022
Home
Subscribe Now